23 March 2026
GSK’s risvutatug rezetecan granted orphan drug designation for SCLC in Japan
Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.